CAPZIX

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: CAPZIX
Generic name: CAPSAICIN
Manufacturer: Toprail Chp Llc.
Product type: HUMAN OTC DRUG
SPL set ID: a4555840-cf8f-45d8-90bb-3581102b58a7
SPL ID: 436cdb27-a019-bc3d-e063-6394a90a45db
Version: 5
Effective date: 2025-11-12
Source export date: 2026-09-28
Source partition: 2
Source file: https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-09-28/f7d2b6e3f8600cd856280ab55a9c6fa54a642647191d164f9d1110e89f3f4097/drug-label-0002-of-0014.json.zip
Source manifest SHA-256: cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run: 20260929T050834Z
Imported at: 2026-09-29 05:14:45

Harmonized routes table
Harmonized routes
TOPICAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 11 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
application number		M017	openfda.application_number
brand name		CAPZIX	openfda.brand_name
generic name		CAPSAICIN	openfda.generic_name
manufacturer name		Toprail Chp Llc.	openfda.manufacturer_name
ndc	package	72847-316-20	openfda.package_ndc
ndc	product	72847-316	openfda.product_ndc
ndc11	package	72847031620	derived:openfda.package_ndc
rxcui		646333	openfda.rxcui
spl id		436cdb27-a019-bc3d-e063-6394a90a45db	id
spl set id		a4555840-cf8f-45d8-90bb-3581102b58a7	set_id
unii		S07O44R1ZM	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

Warnings: For external use only. Avoid contact with eyes. Do not apply to wounds or damaged skin. Do not bandage tightly or apply local heat (such as heating pads) to the area of use. Stop use and ask doctor if condition worsens, or if symptoms persist for more than 7 days or clear up and occur again within a few days. Discontinue use. Keep out of reach of children. If product is swallowed, get medical help or contact a Poison Control Center right away.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.